OABIW | OmniAb, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.2850 - 0.3075
52 Week Range	0.2850 - 0.3075
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	1,588
Average Volume	N/A
Shares Outstanding	1,573,688,219
Market Cap	448,501,152
Sector	Healthcare
Industry	Biotechnology
IPO Date	N/A

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	106
Country	USA
Website	OABIW

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

OABIW's peers: ICUCW, CDIOW

*Chart delayed

Analyzing fundamentals for OABIW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see OABIW Fundamentals page.

Watching at OABIW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on OABIW Technicals page.